WVE WAVE Life Sciences

Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021

Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, November 10, 2021, to discuss its third quarter 2021 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting the “Events” section in the Investor Relations page of the Wave Life Sciences website at . The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 6995569. Following the conference call, an archived version of the call will be available on the website. 

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit  and follow Wave on Twitter @WaveLifeSci.

Investor Contact:

Kate Rausch

617-949-4827



Media Contact:

Alicia Suter

617-949-4817





EN
01/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Wave Life Sciences Ltd: 1 director

Two Directors at Wave Life Sciences Ltd bought/sold 17,115 shares at between 6.688USD and 6.790USD. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...

 PRESS RELEASE

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Pr...

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models  Activin E reduction in lowest single dose cohort of INLIGHT was sustained through six months, supporting once or twice a year dosing Achieved key AATD treatment goals to re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch